Core Viewpoint - The CEO of 基石药业-B (02616.HK), Dr. Yang Jianxin, has demonstrated confidence in the company's long-term investment value by purchasing shares in the open market, indicating a strong belief in the company's ability to maintain stable operations and high-quality growth [1] Share Purchase Details - Dr. Yang purchased a total of 976,000 shares between November 2025 and January 2026, with 428,500 shares bought on January 22 and 23, 2026 [1] - Since becoming CEO in August 2022, Dr. Yang has accumulated a total of 12,477,000 shares [1] - Following this recent purchase, Dr. Yang holds approximately 4.87% of the company's total issued share capital as of the announcement date [1] Confidence in Company - Dr. Yang expressed strong confidence in the company's core competitive advantages and its potential for future growth [1] - He does not rule out the possibility of further increasing his shareholding in the company at an appropriate time [1]
基石药业-B(02616.HK)：首席执行官兼执行董事杨建新近期新增购买97.6万股，累计购买1247.7万股